Orthocell Limited (ASX:OCC)
Australia · Delayed Price · Currency is AUD 0.8800
-0.0250 (-2.76%)
Jan 30, 2026, 9:59 AM AEST
Orthocell Revenue
In the fiscal year ending June 30, 2025, Orthocell had annual revenue of 7.55M AUD with 42.05% growth. Orthocell had revenue of 5.15M in the half year ending June 30, 2025, with 51.51% growth.
Revenue
7.55M
Revenue Growth
+42.05%
P/S Ratio
31.62
Revenue / Employee
n/a
Employees
n/a
Market Cap
238.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.55M | 2.24M | 42.05% |
| Jun 30, 2024 | 5.32M | 1.07M | 25.27% |
| Jun 30, 2023 | 4.24M | 2.71M | 177.01% |
| Jun 30, 2022 | 1.53M | 513.76K | 50.47% |
| Jun 30, 2021 | 1.02M | 298.44K | 41.48% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 95.02M |
| Recce Pharmaceuticals | 7.51M |
| Racura Oncology | 6.04M |
| Starpharma Holdings | 5.85M |
| Botanix Pharmaceuticals | 5.79M |
| Dimerix | 5.59M |
| Actinogen Medical | 5.49M |
| Imugene | 4.40M |
Orthocell News
- 11 days ago - The company repairing human bone with Kimberley pearl shells - The Australian Financial Review
- 3 months ago - Perth biotech Orthocell targets US growth with $25m capital injection - The Australian Financial Review
- 1 year ago - Perth’s billionaire set is piling into this little-known medtech - The Australian Financial Review